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Senescence is a cellular response preventing tumor-
igenesis. The Ras oncogene is frequently activated
or mutated in human cancers, but Ras activation is
insufficient to transform primary cells. In a search
for cooperating oncogenes, we identify the lysine de-
methylase JMJD2A/KDM4A. We show that JMJD2A
functions as a negative regulator of Ras-induced
senescence and collaborates with oncogenic Ras
to promote cellular transformation by negatively
regulating the p53 pathway. We find CHD5, a known
tumor suppressor regulating p53 activity, as a target
of JMJD2A. The expression of JMJD2A inhibits Ras-
mediated CHD5 induction leading to a reduced
activity of the p53 pathway. In addition, we show
that JMJD2A is overexpressed in mouse and human
lung cancers. Depletion of JMJD2A in the human
lung cancer cell line A549 bearing an activated K-
Ras allele triggers senescence. We propose that
JMJD2A is an oncogene that represents a target for
Ras-expressing tumors.
INTRODUCTION
The Ras GTPases are signaling molecules coupling receptor
activation to cellular processes including cell survival, differenti-
ation, and proliferation (Colicelli, 2004). The three cellular Ras
genes encode highly homologous 21 kDa proteins (H-Ras,
N-Ras, and K-Ras). Ras stimulates a complex signaling network
through the activation of a phosphorylation cascade involving
Raf/MEK/ERK, RAL, and PI3K pathways. The small GTP-binding
proteins Ras are frequently mutated in human cancers, particu-
larly in tumors of the lung, pancreas, and colon (Schubbert et al.,
2007). In the majority of cases, missense Ras mutations found in
cancer cells create amino acid substitutions at positions 12, 13,
and 61 that impair the Ras intrinsic and GAP-mediated ability toCell Rehydrolyze GTP, rendering Ras constitutively activated (Kiaris and
Spandidos, 1995). Activation of Ras is not sufficient per se to
transform primary cells, and most of the cancers display muta-
tions in more than one gene. The most frequently mutated
pathways are the receptor tyrosine kinase/Ras/B-Raf signaling
cascade, and the INK4A/CyclinD/Rb and ARF/MDM2/p53
tumor-suppressive pathways (Yeang et al., 2008). Mutations in
genes involved in different pathways can occur in the same
cancer, whereas mutations of genes implicated in the same
pathway are less frequent in the same patient.
Normal cells are protected against transformation mediated
by the activation of oncogenes, such as Ras, by undergoing
a permanent cell-cycle arrest, known as oncogene-induced
senescence (OIS) (Serrano et al., 1997). Whereas murine cells
rely mostly on p53, human cells entering OIS trigger the activa-
tion of the p53 and Rb pathways. Inhibition of these two tumor
suppressors blocks the ability of the cell to trigger OIS following
Ras activation (Ferbeyre et al., 2000; Mallette et al., 2007;
Serrano et al., 1997). OIS constitutes an important tumor-
suppressive mechanism in vivo and can be observed in different
premalignant tumors such as lung adenomas, neurofibromas,
and naevi (Collado et al., 2005; Courtois-Cox et al., 2006;
Michaloglou et al., 2005). The senescence program also con-
tributes to the response to cancer therapy in mouse model of
lymphomas (Schmitt et al., 2002). Furthermore, restoration of
p53 into murine liver carcinomas triggers senescence and tumor
regression in vivo (Xue et al., 2007).
The p53 tumor suppressor pathway is central to the establish-
ment of cellular senescence. This transcription factor regulates
the expression of multiple genes involved in the senescence
response such as the regulator of the cell-cycle p21CIP1 (el-Deiry
et al., 1993), the nuclear body component promyelocytic
leukemia protein (PML) (de Stanchina et al., 2004), and the extra-
cellular matrix component PAI-1 (Kortlever et al., 2006). The
activation of p53 during OIS seems to involve multiple mecha-
nisms, for instance, the DNA damage response and the protein
ARF. The DNA damage response kinase ATM activates p53
during OIS (Bartkova et al., 2006; Di Micco et al., 2006; Mallette
et al., 2007). The phosphorylation of p53 on serine 15 by ATMports 2, 1233–1243, November 29, 2012 ª2012 The Authors 1233
prevents its interaction with the E3 ubiquitin ligase MDM2, thus
avoiding the degradation of p53 (Shieh et al., 1997). The tumor
suppressor ARF is the product of an alternative reading frame
of the INK4A/ARF locus. It is known to stabilize p53 by interact-
ing and sequestering MDM2 to the nucleolus (Weber et al.,
1999). ARF is induced by the activation of Ras and required for
OIS (Ferbeyre et al., 2002). The regulation of the ARF locus by
the Polycomb group (PcG) protein Bmi-1 allows bypass of
senescence by downregulating the expression of INK4A and
ARF (Jacobs et al., 1999). The T-box member Tbx2 also
repressed the ARF locus and was identified for its capacity to
inhibit senescence (Jacobs et al., 2000). More recently, the chro-
modomain helicase DNA-binding domain 5 (CHD5) tumor
suppressor has been shown to be required for Ras-induced
senescence by regulating the INK4A/ARF locus (Bagchi et al.,
2007). CHD5 is a member of the chromatin organizing modulator
domain superfamily harboring two Zinc-binding plant homeodo-
main (PHD) fingers, chromo motifs, and a helicase domain
(Marfella and Imbalzano, 2007). CHD5 is a tumor suppressor
mapping to 1p36, a site frequently deleted or inactivated in
human cancers (Bello et al., 1995; Bie`che et al., 1993; White
et al., 1995).
Histone posttranslational modifications, such as phosphoryla-
tion, ubiquitination, acetylation, and methylation, can modify the
structure of chromatin and also contribute to the formation of
protein complexes controlling gene expression. Among these
modifications, methylation of H3K4 and H3K36 is generally
linked to transcriptionally active genes, whereas H3K9 and
H3K27 are associated with repressed genes. Multiple lysine
methyltransferases are responsible for the methylation of
histones and exert control over gene expression (Kouzarides,
2007). However, the discovery of lysine demethylases showed
that lysine methylation is a reversible and dynamic process.
The Jumonji lysine demethylases are oxygenases catalyzing
the demethylation of mono-, di-, or trimethylated lysines. The
JMJD2 family of lysine demethylases comprises four members
(JMJD2A, JMJD2B, JMJD2C, and JMJD2D) and are Fe(II)- and
a-ketoglutarate-dependent enzymes harboring a JmjC catalytic
domain (Tsukada et al., 2006; Whetstine et al., 2006). JMJD2A,
JMJD2B, and JMJD2C harbor a similar protein structure
including a JmjN domain, a tandem PHD, and a tandem tudor
domain, whereas JMJD2D lacks the PHD and tandem tudor
domains. JMJD2A catalyzes the demethylation of di- and
trimethylated H3K9 and H3K36 and is considered as a transcrip-
tional repressor due to its ability to inhibit expression of its only
known target gene ASCL2 (Klose et al., 2006; Zhang et al.,
2005). JMJD2A also possesses a tandem tudor domain binding
to H3K4(me2/3) and H4K20(me2/3) (Huang et al., 2006; Lee
et al., 2008). Gene amplification of JMJD2C lysine demethylase
has been associated with prostate, breast, esophagus, and brain
cancers (Cloos et al., 2006; Ehrbrecht et al., 2006; Liu et al.,
2009; Yang et al., 2000); however, little is known about the
expression and the role of JMJD2A in cancer.
Here, we demonstrate the important role of JMJD2A in the
inhibition of RasV12-induced senescence by inhibiting the p53
pathway. Depletion of JMJD2A in normal human diploid fibro-
blasts induced a premature cellular senescence phenotype
requiring the p53 tumor suppressor. In order to identify gene1234 Cell Reports 2, 1233–1243, November 29, 2012 ª2012 The Autpromoters regulated by JMJD2A, we performed chromatin
immunoprecipitation (ChIP)-on-chip and discovered the tumor
suppressor CHD5 as a target of JMJD2A. Furthermore, JMJD2A
cooperates with RasV12 and E1A to transform primary cells, and
we report that human lung carcinomas harbor high expression
levels of JMJD2A. We propose that JMJD2A is an oncogene
cooperating with RasV12 to promote tumorigenesis through
the transcriptional repression of CHD5.
RESULTS
Depletion of JMJD2A Induces a p53-Dependent
Senescence Program and JMJD2A Controls the p53
Pathway during OIS
Recently, we showed that JMJD2A is degraded in response to
DNA damage (Mallette et al., 2012) and it was shown that in
Caenorhabditis elegans JMJD2A depletion increases DNA
damage (Whetstine et al., 2006). As DNA damage is a prereq-
uisite for cellular senescence (Mallette et al., 2007), we asked
whether depletion of JMJD2A triggered premature cellular
senescence. We initially examined the role of JMJD2A in cellular
proliferation by depleting JMJD2A in U2OS osteosarcoma cells.
U2OS depleted of JMJD2A by RNA interference displayed
a G0/G1 growth arrest as evidenced by fluorescence-activated
cell sorting (FACS) (Figure S1A). To verify if the observed growth
arrest could be linked to senescence, we then depleted JMJD2A
in the normal human fibroblasts, IMR90. To do this, we trans-
fected IMR90 cells with small interfering RNAs (siRNAs) targeting
JMJD2A (siJMJD2Asp) that efficiently depleted JMJD2A protein
expression (Figure 1A). Compared to cells transfected with
siGFP, cells depleted of JMJD2A exhibited a flattened vacuo-
lated morphology accompanied by a positive staining to the
senescence-associated b-galactosidase assay (SA-b-gal) (Fig-
ure 1B). The use of two additional lentiviral small hairpin RNAs
(shRNAs) targeting JMJD2A also led to the induction of the
senescence phenotype (Figure S1B). A similar phenotype was
observed in mouse embryonic fibroblasts (MEFs) depleted of
JMJD2A using siRNAs (Figures S1C and S1D). An important
hallmark displayed by oncogene-induced senescent cells is
the accumulation of tightly packed chromatin structures named
senescence-associated heterochromatin foci (SAHF). The SAHF
are associated to the accumulation of the heterochromatin asso-
ciated proteins HP1 and increased trimethylated histone H3 on
lysine 9 [H3K9(me3)]. The formation of SAHF seems to be mostly
dependent on the p16/Rb pathway and contributes to the stable
repression of E2F-dependent genes (Narita et al., 2003).
Because JMJD2A catalyzes the demethylation of H3K9(me2/3),
we first considered the possibility that JMJD2A-depleted cells
could accumulate H3K9 methylated histones and form SAHF.
Surprisingly, JMJD2A depletion was insufficient to lead to the
formation of SAHF as evidenced by the absence of H3K9(me3)
foci (Figure 1C). However, the knockdown of JMJD2A led to the
accumulation of PML nuclear bodies (Figure 1C), another well-
characterized senescencemarker (Ferbeyre et al., 2000; Pearson
et al., 2000). The senescence response observed in human cells
relies mostly on the activation of the p53 and/or Rb pathways
(Ferbeyre et al., 2000; Mallette et al., 2007; Serrano et al.,
1997). To define the tumor-suppressor requirement of JMJD2Ahors
Figure 1. JMJD2A Depletion Causes Cell-Cycle Arrest and p53-
Dependent Senescence
(A) Immunoblot analysis of JMJD2A in IMR90 cells transfected with siGFP or
SMARTpool siJMJD2A (siJMJD2Asp) using Lipofectamine RNAiMAX.
(B) SA-b-gal staining of IMR90 cells transfected with siGFP or SMARTpool
siJMJD2A (siJMJD2Asp) using Lipofectamine RNAiMAX. Cells were trans-
fected on day 0 and day 3 and then fixed on day 6 for SA-b-gal activity. The
percentage and SD of SA-b-gal-positive cells are indicated at the bottom right
of each panel. Data represent three independent experiments done with cells
collected 6 days after the initial transfection.
(C) Indirect immunofluorescence of PML and H3K9(me3) in IMR90 cells
infected with a control shRNA (pLKO.1) or an shRNA targeting JMJD2A (sh-
JMJD2A.3 and sh-JMJD2A.5). Cells were fixed for staining on day 8
postselection. The percentage and SD of the cells displaying more than ten
PML nuclear bodies are indicated at the bottom right of each panel. The data
represent the average and SD of three independent counts of 100 cells each.
(D) IMR90 cells infected with shRNAs targeting p16 (sh-p16) or p53 (sh-p53)
were transfected with siGFP or SMARTpool siJMJD2A (siJMJD2Asp) and
stained for SA-b-gal activity. The percentage and SD of SA-b-gal-positive cells
are indicated at the bottom right of each panel. Data represent three inde-
pendent experiments done with cells that were retransfected every 3 days and
fixed for staining 10 days after the initial transfection.
See also Figure S1.depletion-induced senescence, IMR90 cells stably infected with
sh-p16 or sh-p53 were generated. Transfection of siRNAs
targeting JMJD2A triggered senescence in p16-depleted cells
but not in p53-depleted cells (Figures 1D, S1E, and S1F), sug-
gesting that the senescence response triggered by decreasedCell ReJMJD2A levels relies primarily on the p53 pathway. This also sug-
gested that JMJD2A is a potential negative regulator of the p53
pathway. To further investigate this possibility, we examined the
capacity of JMJD2A to block the p53 pathway during Ras-
induced senescence. In IMR90 cells, Ras-induced senescence
depends on either the p53 or the Rb pathway and both pathways
need to be inactivated to rescue the senescence phenotype (Mal-
lette et al., 2007; Serrano et al., 1997). Senescence of Ras-trans-
duced cells was severely impaired when sh-p16 and JMJD2A
expression were combined (Figures 2 and S2). These findings
confirm that JMJD2A negatively controls the p53 pathway.
Together, these results indicate that JMJD2A constitutes a nega-
tive regulator of p53.
CHD5 Is a Transcriptional Target of JMJD2A
To uncover the molecular mechanism by which JMJD2A regu-
lates the p53 pathway, we took advantage of the p53-proficient
U2OS cells, which enter a G0/G1 growth arrest after JMJD2A
depletion (Figure S1A), to identify promoters bound by JMJD2A
using a ChIP-on-chip approach. Using an array covering more
than 10 kb of each gene promoter (from 7,500 to +3,250), we
identified multiple potential target gene promoters bound by
JMJD2A (Table S1). To date, the only known JMJD2A-regulated
gene was the transcription factor ASCL2 (Klose et al., 2006;
Zhang et al., 2005). The identification of the ASCL2 promoter
by ChIP-on-chip validated our approach to discover additional
JMJD2A target genes (Table S1). Among the many JMJD2A
target genes, we identified the chromodomain helicase DNA-
binding domain 5 (CHD5) tumor suppressor. The CHD5 gene,
located at 1p36, is frequently deleted in human cancers and
controls cell proliferation and senescence via the p53 pathway
(Bagchi et al., 2007). To confirm the binding of JMJD2A to
the identified gene promoters, we performed ChIP-qPCR ex-
periments. Again, ASCL2 was enriched by nearly 2-fold in the
flag-JMJD2A immunoprecipitated material (Figure 3A). We also
validated the presence of JMJD2A at the identified gene
promoters including PANX2, RHOQ, PPIC, CDC6, GP5, and
CHD5. Among the two putative JMJD2A-binding sites identified
by ChIP-on-chip on the CHD5 promoter, only the site located
at +741 was enriched by ChIP-qPCR (Figure 3A). We then
used RT-qPCR to validate the regulation of the JMJD2A-bound
target genes at the transcriptional level following JMJD2A deple-
tion. The transfection of U2OS cells using siJMJD2ASMARTpool
led to a dramatic decrease of JMJD2AmRNAbut not of the other
members of the JMJD2 family, JMJD2B, JMJD2C, and JMJD2D
(Figure 3B). Depletion of JMJD2A caused a significant increase
in ASCL2 mRNA levels confirming that JMJD2A acts as a tran-
scriptional repressor as previously reported (Klose et al., 2006;
Zhang et al., 2005). JMJD2A depletion also led to a concomitant
increase of CHD5 mRNA and protein (Figures 3B and 3C). To
eliminate the possible contribution of off-target effects using
the SMARTpool of siRNAs, we also used two different individual
siRNAs deconvoluted from the siJMJD2A SMARTpool to effi-
ciently deplete JMJD2A and observed a concomitant increase
in both ASCL2 and CHD5 mRNA levels (Figures S3A and S3B).
We then looked at the ability of other members of the JMJD2
family of lysine demethylases to regulate the transcript levels
of CHD5. Depletion of JMJD2A, but not of JMJD2B or JMJD2C,ports 2, 1233–1243, November 29, 2012 ª2012 The Authors 1235
Figure 2. JMJD2A Negatively Controls the p53 Pathway during
Oncogene-Induced Senescence
SA-b-gal staining of IMR90 cells infected with an empty vector control or
RasV12, flag-JMJD2A, and/or an shRNA targeting p16 (sh-p16). The
percentage and SD of SA-b-gal-positive cells are indicated at the bottom right
of each panel. Data represent three independent experiments done with cells
fixed for staining on day 8 postselection. See also Figure S2.
1236 Cell Reports 2, 1233–1243, November 29, 2012 ª2012 The Autled to a significant increase of CHD5 (Figure S3C). Interestingly,
PANX2 and RHOQ mRNA levels were also increased following
depletion of JMJD2A, whereas CDC6 levels were not signifi-
cantly regulated (Figure 3B). However, GP5 and PPIC mRNA
levels decreased after treatment with siJMJD2A, suggesting
that JMJD2A may also act as a transcriptional activator (Fig-
ure 3B). To further investigate the role of JMJD2A in the regula-
tion of CHD5, we performed ChIP experiments to assess the
changes in histone methylation of the CHD5 promoter. We
detected an increase of H3K9(me3) levels at the CHD5 promoter
after depletion of JMJD2A (Figure 3D). As a control, we observed
an increase of H3K9(me3) at the ASCL2 promoter in siJMJD2A-
treated cells as previously reported (Klose et al., 2006; Zhang
et al., 2005). Taken together, these results reveal additional
target gene promoters regulated by JMJD2A and identify
CHD5 as a key target of JMJD2A.
To reinforce the link between CHD5 and JMJD2A, we investi-
gated the role of CHD5 during JMJD2A depletion-induced
senescence. To do this, we cotransfected IMR90 cells with
siRNAs targeting JMJD2A and/or CHD5. While JMJD2A-
depleted cells enter senescence, we observed a significant
reduction in the SA-b-Gal staining of cells with the combined
depletion of CHD5 and JMJD2A in the human fibroblasts
IMR90 (Figures 3E and S3D). Similar results were observed in
MEFs (Figures S3E–S3G). JMJD2A depletion caused a signifi-
cant increase of p19ARF protein levels concomitant with the
increase of CHD5 (Figure 4A). Although depletion of JMJD2A
leads to a modest increase in total p53 protein levels, it causes
an important increase in p53 nuclear localization (Figure 4B).
The senescence induced following depletion of JMJD2A not
only required p53, but was also p19ARF dependent as confirmed
by the use of knockout MEFs (Figures 4C and 4D). This suggests
that the p53-dependent senescence program triggered by
decreased JMJD2A levels is mediated by CHD5 via p19ARF.
JMJD2A Blocks OIS-Mediated Activation of p53
To determine the role of JMJD2A in OIS, we examined the
protein levels of JMJD2A during RasV12-induced senescence.
Following introduction of activated Ras in IMR90 cells, JMJD2A
protein levels are significantly decreased, whereas CHD5 and
p21 proteins are increased (Figure 5A). To investigate whether
CHD5 is the target gene by which JMJD2A regulates the p53
pathway during Ras-induced senescence, we looked at the
ability of JMJD2A to repress CHD5 expression in normal human
diploid fibroblasts. According to what we observed in U2OS
cells, JMJD2A depletion in IMR90 cells infected using two
different shRNAs also led to a significant increase of CHD5 (Fig-
ure S4). We then looked at the mRNA and protein levels of the
JMJD2A target genes ASCL2 and CHD5 during OIS. Concomi-
tant with the reduction in JMJD2A previously observed inhors
Figure 3. JMJD2A Binds to the CHD5 Gene and Controls Its Tran-
scriptional Expression
(A) Validation by ChIP-qPCR of selected genes identified by ChIP-on-chip.
U2OS cells were transfected with an empty control vector or flag-JMJD2A and
ChIP was performed using Flag M2 antibody 48 hr after transfection.
(B) Expression levels of mRNA of genes regulated by JMJD2A. U2OS cells
were transfected with siGFP or a SMARTpool targeting JMJD2A (siJMJD2Asp)
using Lipofectamine RNAiMAX and mRNA extracted 72 hr after transfection.
Relative mRNA levels were normalized to GAPDH mRNA.
(C) Immunoblot analysis of CHD5 protein levels in U2OS cells transfected with
siGFP or a SMARTpool targeting JMJD2A (siJMJD2Asp) using lipofectamine
RNAiMAX.
(D) Chromatin immunoprecipitation of H3K9(me3) at the promoters of ASCL2
and CHD5 genes in U2OS transfected with siGFP or siJMJD2Asp.
(E) SA-b-gal staining of IMR90 transfected with siGFP, siJMJD2A-02,
siJMJD2A-03, and siCHD5. The percentage and SD of SA-b-gal-positive cells
are indicated at the bottom right of each panel.
Data represent three independent experiments done with cells that were re-
transfected every 3 days and fixed for staining 10 days after the initial trans-
fection. See also Figure S3.
Figure 4. JMJD2A Depletion-Induced Senescence Requires p19ARF
(A) Immunoblot of p19ARF in MEFs transfected with siGFP or SMARTpool
siJMJD2A (siJMJD2Asp) using Lipofectamine RNAiMAX.
(B) Indirect immunofluorescence against p53 in MEF as prepared in (A).
(C) SA-b-gal staining of wild-type, p53/, and p19ARF/ MEF transfected
with siGFP or siJMJD2Asp. The percentage and SD of SA-b-gal-positive cells
are indicated at the bottom right of each panel. Data represent three inde-
pendent experiments performed with cells that were retransfected every three
days and fixed for staining 10 days after the initial transfection.
(D) Indirect immunofluorescence against PML of the cells prepared in (C). The
percentage and SD of the cells displaying more than ten PML nuclear bodies
are indicated at the bottom left of each panel. The data represent the average
and SD of three independent counts of 100 cells each.Ras-expressing cells,ASCL2 andCHD5mRNA and protein were
strikingly upregulated during RasV12-induced senescence
(Figures 5B and 5C). Ectopic expression of JMJD2A inhibited
the RasV12-induced increase of ASCL2 and CHD5 levels
(Figures 5B and 5C) and led to an associated decrease of the
levels of the p53 target genes p21 and NOXA (Figure 5C). In
some experimental settings, the control of p21 expression by
Ras may be p53-independent (Delgado et al., 2000). To further
support the p53-dependent control of p21 expression exerted
by JMJD2A during OIS, we generated different IMR90 cell lines
expressing an shRNA against p53 (sh-p53) in combination with
RasV12 and JMJD2A. The accumulation of p21 during Ras-
induced senescence in normal human fibroblasts is dependentCell Reon the presence of p53 (Figure 5D). Ectopic expression of
JMJD2A caused a significant decrease of both p53 and p21 in
Ras-expressing cells (Figure 5D). These observations suggest
that JMJD2A negatively controls the Ras-induced activation of
p53 by mediating the repression of CHD5.
JMJD2A Cooperate with Ras Activation in Promoting
Tumorigenesis
To investigate the effect of JMJD2A expression on RasV12-
driven transformation, we took advantage of the experimental
system where RasV12, E1A, and MDM2 cooperate to transform
normal diploid fibroblasts (Seger et al., 2002). We rationalizedports 2, 1233–1243, November 29, 2012 ª2012 The Authors 1237
Figure 5. JMJD2A Blocks RasV12-Mediated p53 Activation
(A) Immunoblot analysis of JMJD2A, CHD5, p21, and a-tubulin as a loading
control in IMR90 cells infected with a control vector or RasV12.
(B) mRNA levels of ASCL2 and CHD5 in IMR90 cells infected with an empty
vector control, H-RasV12 and flag-JMJD2A. RNA was extracted at day 8
postselection and quantitative RT-PCR performed. Relative mRNA levels were
normalized to GAPDH mRNA.
(C) Immunoblot analysis of CHD5 and p53 target genes in IMR90 cells
prepared as in (B).
(D) Immunoblot analysis of p53 and p21 in IMR90 cells expressing different
combinations of H-RasV12, flag-JMJD2A, and sh-p53.
See also Figure S4.
Figure 6. JMJD2A Contributes to the Transformation of Primary
Cells and Is Overexpressed in Mouse Model of Lung Tumors
(A) Tumorigenicity assay using IMR90 cells infected with combinations of
empty vector, E1A, RasV12, JMJD2A, JMJD2AH188A, or MDM2, and injected
subcutaneously in immunocompromised mice.
(B) Immunoblot analysis of flag-JMJD2A expression in tumors observed
following injection of IMR90 cells expressing E1A/RasV12/JMJD2A (E/R/J) or
E1A/RasV12/MDM2 (E/R/M).
(C) Immunohistochemical analysis of JMJD2A protein expression in lungs from
wild-type and K-RasLA2 mice. Scale bar represents 200 mm.that, according to our genetic experiment showing that JMJD2A
negatively controls the p53 pathway during Ras-induced senes-
cence (Figure 2), JMJD2A could replace MDM2 to promote Ras-
mediated transformation. We first infected IMR90 cells with
retroviral vectors encoding RasV12 and E1A. Then, we intro-
duced MDM2, JMJD2A, JMJD2AH188A, or an empty control
vector and injected the selected cells into the flanks of immuno-
compromised mice. As expected, the E1A/RasV12/MDM2 cells
formed tumors at 100% of the injection sites (8/8) (Figure 6A).
The replacement of MDM2 by JMJD2A in combination with
RasV12 and E1A, also significantly promoted the Ras-mediated
formation of cells leading to the formation of tumors at most of
the injection sites (14/22), although less efficiently than the com-
bination withMDM2 (Figure 6A). Mutation of the catalytic domain
of JMJD2A (JMJD2AH188A) completely abolished the ability of
JMJD2A to promote Ras-mediated transformation since no
tumors (0/6) were observed following injection of the E1A/
RasV12/JMJD2AH188A cells (Figure 6A). The catalytic activity of
JMJD2A is then required to cooperate with Ras in cellular trans-
formation. The tumors formed following injection of E1A/
RasV12/JMJD2A displayed high levels of flag-tagged JMJD2A,
confirming that these tumors arose from the initial JMJD2A-
expressing fibroblasts (Figure 6B). These results strongly1238 Cell Reports 2, 1233–1243, November 29, 2012 ª2012 The Autsuggest that JMJD2A cooperates with Ras in promoting cell
transformation by negatively regulating the p53 pathway.
To further investigate the role of JMJD2A in Ras-mediated
tumorigenesis, we used the K-RasLA2 mouse model of lung
carcinomas (Johnson et al., 2001). K-Ras activation led to the
formation of tumors displaying strong JMJD2A-positive staining,
whereas lungs of wild-type littermates showed weak staining
(Figure 6C).
To examine the role of JMJD2A in human cancer, we analyzed
several human lung carcinomas in which Ras mutations occurhors
Figure 7. JMJD2A Is Overexpressed in Human Lung Tumors and Depletion of JMJD2A Triggers Senescence in the Human Lung Cancer Cell
Line A549
(A) Immunohistochemical analysis of JMJD2A protein expression in human lung carcinomas and normal lung tissues. Scale bar represents 50 mm.
(B) Immunohistochemical score (IHS) of 10 normal lung tissues and 108 lung carcinomas immunostained for JMJD2A as displayed in (A). An IHS score >3 was
considered as positive expression.
(C) SA-b-gal staining of A549 human lung cancer cells infected with lentiviral vectors pLKO.1 or shRNA against JMJD2A. The percentage and SD of SA-b-gal-
positive cells are indicated at the bottom right of each panel. Data represent three independent experiments done with cells collected 8 days postselection.
(D) Growth curve of A549 human lung cancer cells infected with lentiviral vectors pLKO.1 or shRNA against JMJD2A as in (C).
See also Figure S5.frequently (Schubbert et al., 2007). We observed high levels of
JMJD2A in nearly 17% (18/108) of the human lung carcinomas,
whereas none of the normal lung tissue (0/10) displayed JMJD2A
expression (Figures 7A and 7B). Furthermore, the JMJD2A stain-
ing was intense in lung carcinomas but absent in normal lung
tissues (Figure 7B). To study the role of JMJD2A in cancer cell
growth, we depleted JMJD2A in the human lung cancer cell
line A549 bearing an activated K-Ras allele. Interestingly, deple-
tion of JMJD2A in A549 cells led to the establishment of senes-
cence and growth arrest, suggesting that JMJD2Aplays a crucial
role in the growth of Ras-expressing cancer cell lines (Figures 7C
and 7D). We further test the cellular response to JMJD2A knock-
down in different normal fibroblasts (WI-38 and BJ) and cancer
cell lines (MCF7, HeLa, and 293T). The depletion of JMJD2A
caused defects in proliferation of the p53-proficient WI-38, BJ,
and MCF7, but not in the p53-inactivated 293T and HeLa
(Figures S5A and S5B). This reduced proliferation observed
was not associated with cell death, but displayed features of
senescence (Figures S5C and S5D). Taken together, these
results reveal that JMJD2A is an oncogene cooperating with
RasV12 in promoting cellular transformation by negatively
controlling the p53 pathway through the transcriptional repres-
sion of the tumor suppressor CHD5.Cell ReDISCUSSION
Understanding the molecular mechanisms leading to the estab-
lishment of tumor suppression such as OIS is crucial for the
development of innovative therapeutics for blocking tumor
progression. Based on the results presented here, we define
a molecular pathway contributing to the activation of p53 during
OIS. The lysine demethylase JMJD2A is known to catalyze the
removal of di- and trimethyl groups from lysine 9 and 36 of
histone H3. Here we describe that JMJD2A depletion is sufficient
to trigger a p53-dependent senescence response (Figure 1D)
and ectopic expression of JMJD2A is able to negatively regulate
p53 during OIS (Figure 5). Taken together, these results strongly
suggest that JMJD2A negatively regulates p53. Using ChIP, we
identified a myriad of JMJD2A target genes including the tumor
suppressor CHD5 (Figure 3). CHD5 plays an important role in the
activation of p53 during OIS (Bagchi et al., 2007) and the CHD5
gene is frequently deleted in human cancers (Bello et al., 1995;
Bie`che et al., 1993; White et al., 1995). We show that ectopic
expression of JMJD2A hinders Ras-induced expression of
CHD5 leading to p53 activation defects (Figures 5B–5D). The
increased PML nuclear bodies observed following JMJD2A
depletion (Figure 1C) also indicates that JMJD2A negativelyports 2, 1233–1243, November 29, 2012 ª2012 The Authors 1239
controls p53 activation, since PML is a transcriptional target of
p53 (de Stanchina et al., 2004). However, ectopic expression
of JMJD2A does not completely abrogate the expression of
p53 target genes (Figures 5C and 5D) and the residual p53 acti-
vation observed in cells expressing both Ras and JMJD2Amight
explain the less efficient transformation mediated by JMJD2A
compared to MDM2 (Figure 6A). This implies that other molec-
ular pathways contribute to p53 activation during OIS. In fact,
a DNA damage response caused by replicative stress (Di Micco
et al., 2006), as well as reactive oxygen species (Mallette and
Ferbeyre, 2007) is initiated by oncogenic activation in normal
cells. This DNA damage response triggered by the PIK-related
kinase ATM is required to activate p53 during OIS (Bartkova
et al., 2006; Di Micco et al., 2006; Mallette et al., 2007). Downre-
gulation of JMJD2A and the DNA damage response could
possibly cooperate to achieve full p53 activation during OIS.
The CHD5 tumor suppressor is frequently deleted in human
cancers (Bello et al., 1995; Bie`che et al., 1993; White et al.,
1995). Here, we describe a mechanism of inactivation of CHD5
through the transcriptional repression mediated by JMJD2A.
This suggests that the increased JMJD2A expression observed
in lung tumors of human andmice could contribute to the control
of the p53 pathway through the control of CHD5. Recently, it has
been demonstrated that CHD5 protein levels are low or absent in
lung cancer and that enforced expression of CHD5 in lung
cancer cell lines causes a significant decrease in clonogenicity
(Zhao et al., 2012). The elevated JMJD2A expression observed
in lung tumors of both human and mouse could contribute to
the reduction of CHD5 levels. Furthermore, JMJD2A expression
can replace the MDM2 oncogene in Ras-mediated trans-
formation of normal diploid fibroblasts confirming its capacity
to negatively regulate the p53 pathway (Figure 6A). Altogether,
our results imply that JMJD2A cooperates with Ras during
tumorigenesis.
The expression of the lysine demethylase JMJD2C is signifi-
cantly increased in prostate cancer compared to normal tissue
(Cloos et al., 2006), but the levels of JMJD2A in cancer tissues
remained to be determined. Here we show that JMJD2A levels
are also elevated in lung adenocarcinomas and that JMJD2A
cooperates with Ras-mediated tumorigenesis by restraining
p53 activation. Interestingly, JMJD2A seems to be essential for
different cancer cell lines since its depletion triggers either
apoptosis (Kim et al., 2012) or senescence (Figure 7C), thus
limiting the proliferation potential of the cells. JMJD2A also
seems to be required for tumor cell invasion and migration in
breast cancer (Li et al., 2011). JMJD2A has been linked to the
control of the cell cycle by regulating DNA replication and chro-
matin accessibility (Black et al., 2010). As demonstrated also by
Black et al. (2010), depletion of JMJD2A in 293T cells does not
cause proliferation defects or senescence and this is due to
the lack of a functional p53 tumor suppressor pathway in 293T
cells (Figure S5).
Since its discovery, the JMJD2A lysine demethylase has been
proposed to act as a transcriptional repressor. JMJD2A has
been identified as an interacting protein with the transcriptional
repressor complex N-CoR including HDAC1 and HDAC3 (Gray
et al., 2005; Zhang et al., 2005). Depletion of JMJD2A has
been shown to trigger the accumulation of H3K9(me3) levels1240 Cell Reports 2, 1233–1243, November 29, 2012 ª2012 The Autand lead to a concomitant increase in ASCL2 gene expression
(Figure 3) (Klose et al., 2006; Zhang et al., 2005). We now extend
the list of JMJD2A transcriptionally repressed target genes with
the identification of CHD5, PANX2, and RHOQ (Figures 3A and
3B). Although we confirm that JMJD2A can act as a transcrip-
tional repressor, we also identified JMJD2A-activated genes
(GP5 and PPIC), suggesting that JMJD2A could also act as a
transcriptional activator. Although CDC6 is an interesting candi-
date, we were unable to validate it as a transcriptional target of
JMJD2A (Figure 3B). The choice between activation and repres-
sionmay be dictated by the chromatin structure, the presence or
absence of other transcriptional regulators, and environmental
stresses such as hormone stimulation.
Senescence represents an excellent cellular model to study
putative oncogenes cooperating with Ras. The exploitation of
the requirement of the ARF/p53 and INK4A/Rb pathways during
Ras-induced senescence allowed the identification of additional
regulators of these pathways. Among them, KLF4 caused the
bypass of OIS through the transcriptional repression of p53
(Rowland et al., 2005), and hDRIL1 led to activation of E2F1 to
inhibit OIS (Peeper et al., 2002). Here, we identify JMJD2A as
an oncogene cooperating with Ras through its ability to suppress
cellular senescence. Furthermore, JMJD2A depletion triggers
a senescence response, suggesting that its inactivation by small
molecule inhibitors might trigger senescence in cancer cells.
Clinically, some treatments rely on their capacity to force cancer
cells into a senescent state (Ewald et al., 2010; Nardella et al.,
2011). Recent studies indicate that cellular senescence plays
a crucial role in the suppression of oncogene-induced tumori-
genesis in vivo (Braig et al., 2005; Chen et al., 2005; Collado
et al., 2005; Lin et al., 2010; Michaloglou et al., 2005; Ventura
et al., 2007; Xue et al., 2007).EXPERIMENTAL PROCEDURES
Cells, Vectors, and Retroviral Infections
Human diploid fibroblasts IMR90, WI-38, BJ, MEF, MEF p53/, MEF
p19ARF/, MCF7, A549, HeLa, 293T, and osteosarcoma cells U2OS (ATCC)
were cultured in Dulbecco’s modified Eagle medium supplemented with
10% fetal bovine serum (FBS) (Hyclone) and antibiotics. The following retro-
viral vectors were used: pLPC-puro, pWZL-hygro E1A, pWZL-Blast RasV12,
MSCV-sh-p16, pRS-sh-p53, and pWZL-neo MDM2 (Narita et al., 2006). The
pLPC-puro flag-JMJD2A was generated by introducing an amino-terminal
flag epitope by PCR and cloning into the BamHI site of pLPC-puro. Retroviral
infections, cell-cycle analysis, and senescence-associated b-galactosidase
assays were carried out as described previously (Mallette et al., 2007).
Western Blot Analysis and Immunofluorescence
For western blotting, cells were lysed in 20 mM Tris (pH 7.5), 150 mM NaCl,
1 mM EDTA, 1 mM EGTA, 1% Triton X-100, and EDTA-free protease inhibitors
(Complete, Roche) and sonicated three times for 10 s each. Proteins were
separated on SDS-PAGE and transferred to nitrocellulose membranes (Bio-
Rad). Primary antibodies used were anti-a-tubulin (B-5-1-2, Sigma, 1:5,000),
anti-Flag (M2, Sigma, 1:4,000), anti-JMJD2A (NB110-40585, Novus Bio-
logicals, 1:1,000), anti-CHD5 (ab66516, Abcam, 1:500), anti-p53 HRP-
conjugated (HAF1355, R&D Systems, 1:5,000), anti-p16 (F-12, Santa Cruz,
1:500), anti-p21 (05-345, Millipore, 1:1,000), anti-p19ARF (Ab80, Abcam,
1:1,000), and anti-NOXA (114C307, EMD, 1:500).
For immunofluorescence, IMR90 cells infected with different combinations
of retroviral plasmids were grown on coverslips in 6-well plates. Cells were
fixed in 4% paraformaldehyde for 15 min and permeabilized with PBS, 3%hors
BSA, 0.2% Triton X-100 for 5 min. Cells were then washed three times with
PBS and 3% BSA and stained with anti-Flag (M2, Sigma, 1:400), anti-HP1a
(2616, Cell Signaling, 1:400), anti-H3K9(me3) (AR-0170, Lake Placid Biologi-
cals, 1:400), anti-p53 (2524, Cell Signaling, 1:400), or anti-PML (PG-M3, Santa
Cruz Biotechnology, 1:400). Alexa Fluor 488- or Alexa Fluor 546-conjugated
secondary antibodies (Molecular Probes, 1:1,000) were used.
shRNA Lentiviral Infections and siRNA Transfections
The pLKO.1 lentiviral vectors containing shRNAs pLKO.1-shJMJD2A.3
(RHS3979-9581182) and pLKO.1-shJMJD2A.5 (RHS3979-9581184) were
obtained from OpenBiosystems. To produce lentiviral particles, 293T cells
were transfected using 9 mg of pLKO.1 shRNA plasmid, 6.75 mg of psPAX2
packaging plasmid, and 2.25 mg pMD2.G envelope plasmid. Media was
changed 24 hr after transfection and lentiviral particles were harvested 48 hr
after transfection. Viral supernatant was filtered through 0.45 mm filters and
then supplemented with 4 mg/ml polybrene and 10% FBS. The list of siRNAs
used is provided in the Extended Experimental Procedures.
Subcutaneous Tumorigenicity Assay
Cells were assessed for in vivo tumorigenicity as described (Seger et al., 2002).
Briefly, IMR90 cells were infected with a combination of pWZL-hygro E1A,
pWZL-Blast RasV12, and a control vector pLPC-puro, pLPC-puro flag-
JMJD2A, pLPC-puro flag-JMJD2AH188A, or pWZL-neo MDM2 and injected
in the flank of 8-week-old immunocompromised athymic nude mice. Cells
(5 3 106) were resuspended in 100 ml of sterile PBS and injected using
a 25 gauge needle into anesthetized mice. The mice were monitored daily
and were handled and sacrificed in accordance with a protocol approved by
the Animal Care Committee at McGill University.
Immunohistochemistry Staining
Lungs from wild-type or K-RasLA2 mice and human lung carcinomas and
normal tissue array (BC041115, US Biomax) were tested using immunohisto-
chemistry staining according to manufacturer recommendations on an
automated immunostainer (Discovery XT system, Ventana Medical Systems,
Tucson, AZ, USA). Antigen retrieval was performed with proprietary reagents.
JMJD2A (5328, Cell Signaling, 1:20) antibody was applied on every sample for
60 min at room temperature. Sections were then incubated with a specific
secondary biotinylated antibody. Streptavidin horseradish peroxidase, and
3,30-diaminobenzidine were used according to themanufacturer’s instructions
(Ventana Medical Systems). Finally, sections were counterstained with
hematoxylin.
As for quantitative assessment, slides were scanned using the
Hamamatsu’s NanoZoomer 2.0-HT Digital Pathology system. Virtual slides
were then uploaded on a server dedicated to histology facility users, http://
www.histo.iric.ca, and visualized with the mScope Education Portal 3.6.2
(Aurora, Montreal). The expression level of JMJD2A was evaluated by the
pathologist by combining an estimate of the percentage of immunoreactive
cells (quantity score) with an estimate of the staining intensity (staining
intensity score). For instance, less than 10% labeled cells were scored as 1,
10%–50% as 2, 50%–70% as 3, and 70%–100% as 4. Staining intensity
was rated on a scale from 0 to 3 as follows: 0 = negative, 1 = weak, 2 =
moderate, and 3 = strong. The raw data were then converted to the immuno-
histochemical score (IHS) by multiplying the quantity and the staining intensity
scores. Therefore, the score could range from 0 to 12. A IHS score >3 was
considered as positive expression.
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